Management of patients with generalised myasthenia gravis and COVID-19: four case reports
Annemarie Hübers, Agustina M. Lascano, Patrice H. Lalive
Abstract
Comment on : International MG/COVID-19 Working Group; Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020 May 15;412:116803. <a href="https://doi.org/10.1016/j.jns.2020.116803" rel="noopener noreferrer" target="_blank">doi: 10.1016/j.jns.2020.116803</a>. Epub 2020 Mar 25. <a href="https://pubmed.ncbi.nlm.nih.gov/32247193/" rel="noopener noreferrer" target="_blank">PMID: 32247193</a>; PMCID: PMC7105910.
Topics & Concepts
Myasthenia gravisMedicinemyalgiaPyridostigmineAzathioprinePrednisoneInternal medicineCoronavirus disease 2019 (COVID-19)Neuromuscular diseaseMuscle weaknessPediatricsDiseaseInfectious disease (medical specialty)Myasthenia Gravis and ThymomaLong-Term Effects of COVID-19